公司資料
Beam Therapeutics 股價、新聞與催化劑
- 股票代碼:
- BEAM
- 交易所:
- NASDAQ
- 產業:
- Biopharma
- 所在地:
- United States
股票表現
27.10 USD (+1.31%)
收盤價
最後更新: 2026年8月17日
2.98B USD
市值
股價為何變動
As of Aug 17, 2026, BEAM closed up 1.31% at $27.10. No new same-company headline was identified in the current news window.
公司概覽
Base Editing
Beam Therapeutics develops precision genetic medicines using base editing, which can change individual DNA bases without creating double-strand breaks. The company integrates editing, delivery and manufacturing capabilities.
BEAM-302
BEAM-302 is an in vivo liver-editing candidate for alpha-1 antitrypsin deficiency and is moving into a global pivotal cohort.
BEAM-301
BEAM-301 is an in vivo base-editing therapy for glycogen storage disease type Ia that has entered clinical evaluation.
BEAM-304
BEAM-304 is a liver-directed base-editing candidate for phenylketonuria and is preparing for an IND submission.
Sickle Cell Disease
Risto-cel is an ex vivo base-edited hematopoietic stem-cell therapy for sickle cell disease and is approaching a potential U.S. regulatory submission.
未來催化劑
- Initiation of a global pivotal cohort for BEAM-302 in the second half of 2026.
- IND submission for BEAM-304 during 2026.
- Additional BEAM-301 clinical data during 2026.
- BLA submission for risto-cel as early as year-end 2026.
近期新聞
- 01
- 02
- 03
- 04
- 05
相似股票
商業成熟度、治療領域或催化劑模式相近的同業公司。